Efficacy of trabectedin in advanced soft tissue sarcoma: Beyond lipo- and leiomyosarcoma

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 5785-5791

  De Sanctis, Rita ^a   Marrari, Andrea ^a   Marchetti, Silvia ^a   Mussi, Chiara ^a   Balzarini, Luca ^b   Lutman, Fabio Romano ^b   Daolio, Primo ^c   Bastoni, Stefano ^c   Bertuzzi, Alexia Francesca ^a,d   Quagliuolo, Vittorio ^a   Santoro, Armando ^a  

^a Department of Medical Oncology and Haematology ^*  (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^d Floor 1   (Ireland)

Author keywords

Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma; Trabectedin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CLASSIFICATION; COHORT ANALYSIS; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM SARCOMA; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FIBROSARCOMA; HEMATOTHORAX; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NEUROECTODERM TUMOR; NEUTROPENIA; OVERALL SURVIVAL; PLEOMORPHIC SARCOMA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; FOLLOW UP; METASTASIS; MIDDLE AGED; PATHOLOGY; SARCOMA; SURVIVAL RATE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SARCOMA; SURVIVAL RATE; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945967459     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S92395     Document Type: Article

References (25)

1. Germano G, Frapolli R, Belgiovine C, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23(2):249-262.
2. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs. 2007;67(15):2257-2276.
3. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188-4196.
4. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8(7):595-602.
5. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009;20(8):1439-1444.
6. Movva S, Verschraegen C. Systemic management strategies for metastatic soft tissue sarcoma. Drugs. 2011;71(16):2115-2129.
7. Le Cesne A, Ray-Coquard I, Duffaud F, et al. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur J Cancer. 2015;51(6):742-750.
8. Demetri GD, von Mehren M, Jones RL, et al. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) [abstract]. J Clin Oncol. 2015;33(Suppl):A10503.
9. Mertens F, Antonescu CR, Hohenberger P, et al. Translocation-related sarcomas. Semin Oncol. 2009;36(4):312-323.
10. Di Giandomenico S, Frapolli R, Bello E, et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene. 2014;33(44):5201-5210.
11. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28(33):4996-5010.
12. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187-3205.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
14. National Institutes of Health/National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4. 03; 2009. Available from: http://www.eortc.be/services/doc/ctc/. Accessed June 27, 2014.
15. Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res. 1998;4(5):1079-1086.
16. Blay JY, Leahy MG, Nguyen BB, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014;50(6):1137-1147.
17. Le Cesne A, Cresta S, Maki RG, et al. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer. 2012;48(16):3036-3044.
18. Le Cesne A, Judson I, Maki R, et al. Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer. 2013;109(7):1717-1724.
19. Sanfilippo R, Dileo P, Blay JY, et al. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs. 2015;26(6):678-681.
20. Schöffski P, Dumez H, Wolter P, et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Exp Opin Pharmacother. 2008;9(9):1609-1618.
21. Schöffski P, Taron M, Jimeno J, et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer. 2011;47(7):1006-1012.
22. Italiano A, Laurand A, Laroche A, et al. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. Cancer. 2011;117(15):3445-3456.
23. Martin-Liberal J, Judson I. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas. Exp Opin Drug Saf. 2013;12(6):905-911.
24. Cousin S, Blay JY, Bertucci F, et al. Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. Ann Oncol. 2013;24(10):2681-2685.
25. Penel N, Demetri GD, Blay JY, et al. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol. 2013;24(2):537-542.